Navigation Links
Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/13/2008

Presentation Scheduled for Monday, March 17th at 11:30am ET

NEW YORK, March 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, and Eric Grossman, MD, the Company's Vice President, Medical Affairs, are scheduled to present at the Cowen and Company Health Care Conference being held in Boston.

The presentation, which will take place on Monday, March 17th at 11:30am ET, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing ZerenexTM (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
4. Keryx Biopharmaceuticals Announces Additions to Management Team
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
10. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolyti...s" or the "Company") today announced updated resul...) in patients with sarcomas metastatic to the lung...ctive Tissue Oncology Society Meeting held in Miam...ster presentation, entitled "A Phase II Study of I...
(Date:11/5/2009)...TRANSPORTATION -- Gone hybrid . . . , Fuel eco...es are now posted at the www.fueleconomy.gov web...ed and maintains for the U.S. Department of Energy...e of the top 10 vehicles on the best fuel economy ... (51 MPG city; 48 highway). "This list proves that...
(Date:11/5/2009)... PARSIPPANY, N.J., Nov. 5 DSM Phar...de a manufacturing alliance with Galenix, Saint Je...d commercial scale manufacturing partner for Galen...M and Galenix will collaborate on business develop...ery technologies, based on the strength of Galenix...
(Date:11/5/2009)... Conference Call on Thursday, November 5, 2009 at ...OUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Ph... (NASDAQ: OGXI ) today reported unaudited financi...nded September 30, 2009 and reviewed the Company,s...he following consolidated results reflect the oper...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...roach to Modeling Complex Biologic... April 30 Genstruct Inc., a systems,biology compa...tworks and,biomarkers to better understand large s...boration with Sirtris Pharmaceuticals, Inc. (Nasda...discovering and developing small,molecule drugs to...
...s,Corporation (NYSE: CSC ) today announced that D...resident of its North American Public Sector,busin...ician and Modern,Healthcare magazines, annual rank...published in April. Readers from both magazines no...annual ranking. Of the top 100,most-nominated cand...
...stCall/ -- Huifeng,Bio-Pharmaceutical Technology, ...er and producer of plant extracts and pharmaceutic...eutical and food production, today,announced that ...quarter,ended March 31 on Thursday, May 15, 2008, ...ease and related materials will be available on th...
Other Biology Technology:Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2CSC's Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List 2
(Date:11/4/2009)...obal Rainmakers, Inc., an intellectual property ho...ay announced that the company has exited its "stea...e its suite of technologies designed to leverage c...ring the past four years, the company has spent te...series of core--but expandable--technologies built...
(Date:11/4/2009)...coe Software, Inc., the commercial arm of the Open.../openmicroscopy.org ), is proud to announce its c...logy,s exciting new project titled "The Cell: An I...timulus grant through the National Institutes of H... of the American Reinvestment and Recovery Act, to...
(Date:11/3/2009)...r of the ocean, cruising thousands of miles in a s...ered that the sharks have maintained such a consis...nds of years the white sharks in the northeastern ...ulation genetically distinct from sharks elsewhere...ly mobile species," said Salvador Jorgensen, a pos...
Breaking Biology News(10 mins):Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4The tourist trap 9540 1BELLUS Health reports results for first half of fiscal 2009 54277 1BELLUS Health reports results for first half of fiscal 2009 54277 2BELLUS Health reports results for first half of fiscal 2009 54277 3BELLUS Health reports results for first half of fiscal 2009 54277 4BELLUS Health reports results for first half of fiscal 2009 54277 5BELLUS Health reports results for first half of fiscal 2009 54277 6BELLUS Health reports results for first half of fiscal 2009 54277 7BELLUS Health reports results for first half of fiscal 2009 54277 8BELLUS Health reports results for first half of fiscal 2009 54277 9BELLUS Health reports results for first half of fiscal 2009 54277 10BELLUS Health reports results for first half of fiscal 2009 54277 11BELLUS Health reports results for first half of fiscal 2009 54277 12BELLUS Health reports results for first half of fiscal 2009 54277 13BELLUS Health reports results for first half of fiscal 2009 54277 14BELLUS Health reports results for first half of fiscal 2009 54277 15BELLUS Health reports results for first half of fiscal 2009 54277 16BELLUS Health reports results for first half of fiscal 2009 54277 17BELLUS Health reports results for first half of fiscal 2009 54277 18BELLUS Health reports results for first half of fiscal 2009 54277 19BELLUS Health reports results for first half of fiscal 2009 54277 20BELLUS Health reports results for first half of fiscal 2009 54277 21BELLUS Health reports results for first half of fiscal 2009 54277 22BELLUS Health reports results for first half of fiscal 2009 54277 23BELLUS Health reports results for first half of fiscal 2009 54277 24BELLUS Health reports results for first half of fiscal 2009 54277 25BELLUS Health reports results for first half of fiscal 2009 54277 26BELLUS Health reports results for first half of fiscal 2009 54277 27BELLUS Health reports results for first half of fiscal 2009 54277 28Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 1Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 2Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 3Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 4Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 5Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 6
...shade trees may improve crops, resistance to tempe...nges are expected to trigger, according to an arti.... The article, by Brenda B. Lin, Ivette Perfecto, ..., focuses on coffee production, although their con... important crops, including cocoa and tea, which a...
...Biometric Access Control Solution, ...., Sept. 30 BIO-key International,Inc. (OTC Bulle...ty,solutions and finger-based biometric identifica...nte"), a leading accounting and consultant firm, h...to secure their new,headquarters., Parente, headq...
...American Scientists (FAS) will reach new levels wi...te immunology video game through a generous grant ...d fun game is available for download at http://fa...next version of Immune Attack in February 2009," s...earning Technologies Program. "We,re interested i...
Other Biology News:Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 2Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 3Entertainment Software Association Foundation awards grant to FAS for immune attack 2
Rabbit Anti-Bcl-G, C-Terminus Polyclonal Antibody, Unconjugated from AnaSpec
Rabbit Anti-Mouse sRANKL Antibody, Biotin Conjugated from Cell Sciences
Rabbit Anti-L-isoleucine Antibody, Unconjugated from QED Bioscience Inc.
Anti-TIMP-4 (Tissue Inhibitor of Metalloproteinases-4), Loop #3 Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: